Selected Grantee Publications
Fetal Bone Engraftment Reconstitutes the Immune System in Pigs With Severe Combined Immunodeficiency
Monarch et al., Lab Animal. 2024.
https://pubmed.ncbi.nlm.nih.gov/39289566/
A valuable preclinical model for studying immune-related pathologies is the severe combined immunodeficiency (SCID) pig through modification of recombination activating gene 2 (RAG2) and interleukin-2 receptor-γ (IL2RG). RAG2/IL2RG double knockout SCID pigs are hard to maintain for breeding and long-term studies because their life span is 8 weeks or less. The researchers investigated fetal allograft transplantation derived from immunocompetent pigs as a strategy for reconstituting the immune system of SCID pigs and promoting survival. Following fetal allograft, SCID pigs demonstrated increased levels of lymphocytes. SCID pigs that received the fetal allograft demonstrated improved body condition and extended life span compared with nonrecipient SCID littermates. This study demonstrates the potential use of fetal allograft transplantation to extend the life span of SCID pigs to breeding age to reduce the resources used to maintain this model for biomedical research. Supported by ORIP (U42OD011140, R21OD027062).
Intrinsic Link Between PGRN and GBA1 D409V Mutation Dosage in Potentiating Gaucher Disease
Lin et al., Human Molecular Genetics. 2024.
https://doi.org/10.1093/hmg/ddae113
Gaucher disease (GD) is an autosomal recessive disorder and one of the most common lysosomal storage diseases. GD is caused by mutations in the GBA1 gene that encodes glucocerebrosidase (GCase), a lysosomal protein involved in glyocolipid metabolism. Progranulin (PGRN, encoded by GRN) is a modifier of GCase, and GRN mutant mice exhibit a GD-like phenotype. The researchers in this study aimed to understand the relationship between GCase and PGRN. They generated a panel of mice with various doses of the GBA1 D409V mutation in the GRN-/- background and characterized the animals’ disease progression using biochemical, pathological, transcriptomic, and neurobehavioral analyses. Homozygous (GRN-/-, GBA1 D409V/D409V) and hemizygous (GRN-/-, GBA1 D409V/null) animals exhibited profound inflammation and neurodegeneration compared to PG96 wild-type mice. Compared to homozygous mice, hemizygous mice showed more profound phenotypes (e.g., earlier onset, increased tissue fibrosis, shorter life span). These findings offer insights into GD pathogenesis and indicate that GD severity is affected by GBA1 D409V dosage and the presence of PGRN. Supported by ORIP (R21OD033660) and NINDS.
Establishing an Immunocompromised Porcine Model of Human Cancer for Novel Therapy Development with Pancreatic Adenocarcinoma and Irreversible Electroporation
Hendricks-Wenger et al., Scientific Reports. 2021.
https://pubmed.ncbi.nlm.nih.gov/33828203/
Efficacious interventions to treat pancreatic cancer lack a preclinical model to recapitulate patients' anatomy and physiology. The authors developed RAG2/IL2RG deficient pigs using CRISPR/Cas9 with the novel application of cancer xenograft studies of human pancreatic adenocarcinoma. These pigs were successfully generated using on-demand genetic modifications in embryos. Human Panc01 cells injected into the ears of RAG2/IL2RG deficient pigs demonstrated 100% engraftment. The electrical properties and response to irreversible electroporation of the tumor tissue were found to be similar to excised human pancreatic cancer tumors. This model will be useful to bridge the gap of translating therapies from the bench to clinical application. Supported by ORIP (R21OD027062), NIBIB, and NCI.